SEC Company Response from KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA) — Aug 29, 2018
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: Aug. 29, 2018 · CIK: 0001075880 · Accession: 0001193125-18-261409
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226240
Letter
via EDGAR Division of Corporation Finance 100 F Street, N.E. Washington, D.C. USA Attention: Ada D. Sarmento
Dear Ms. Sarmento:
Re: Kazia Therapeutics Limited
Registration Statement on Form F-3, as amended
Filed: July 19, 2018
File No. 333-226240
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kazia Therapeutics Limited (the “Company”) hereby requests acceleration of its Registration Statement on Form F-3 (File No. 333-226240), as amended, so that it will become effective on August 30, 2018, at 4:30 p.m. (Washington D.C. time), or as soon thereafter as practicable.
The Company hereby acknowledges that:
1. should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
3. the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions, or require any additional information, please do not hesitate to call Nathaniel Douglas at Baker McKenzie, the Company’s outside counsel, at (202) 835-4277.
Sincerely yours,
/s/ Kate Hill
Show Raw Text
CORRESP 1 filename1.htm CORRESP Kazia Therapeutics Limited Level 24, Three International Towers 300 Barangaroo Avenue Sydney, NSW 2000, Australia August 28, 2018 via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 USA Attention: Ada D. Sarmento Dear Ms. Sarmento: Re: Kazia Therapeutics Limited Registration Statement on Form F-3, as amended Filed: July 19, 2018 File No. 333-226240 Pursuant to Rule 461 under the Securities Act of 1933, as amended, Kazia Therapeutics Limited (the “Company”) hereby requests acceleration of its Registration Statement on Form F-3 (File No. 333-226240), as amended, so that it will become effective on August 30, 2018, at 4:30 p.m. (Washington D.C. time), or as soon thereafter as practicable. The Company hereby acknowledges that: 1. should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; 2. the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3. the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you have any questions, or require any additional information, please do not hesitate to call Nathaniel Douglas at Baker McKenzie, the Company’s outside counsel, at (202) 835-4277. Sincerely yours, /s/ Kate Hill Kate Hill Company Secretary 1